Ekso Bionics reports Q2 EPS ($1.24) vs. ($1.99) last year

Reports Q2 revenue $2.06M vs. $4.95M last year. “While there was abnormal weakness in the second quarter, in large part due to what we believe are short-term delays in completing some multi-device Enterprise Health sales, we are working to get back on track for the second half of the year and beyond,” said Scott Davis, the company’s CEO. “In addition to pulling in those aforementioned sales deferrals and continuing to meet anticipated Enterprise Health customer demand, we expect that to be bolstered by an increasing contribution from our Personal Health products, which grew by more than 50% year-over-year in the first half of 2025.”